Co-Authors
This is a "connection" page, showing publications co-authored by Kevin Ariën and Cyril Barbezange.
Connection Strength
0.294
-
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J. 2022 02; 59(2).
Score: 0.062
-
Prevalence and incidence of anti-SARS-CoV-2 antibodies among healthcare workers in Belgian hospitals before vaccination: a prospective cohort study. BMJ Open. 2021 06 29; 11(6):e050824.
Score: 0.060
-
Persistence of IgG response to SARS-CoV-2. Lancet Infect Dis. 2021 02; 21(2):163-164.
Score: 0.057
-
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020 Dec 14; 21(1):1024.
Score: 0.057
-
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020 Nov 27; 21(1):981.
Score: 0.057